ALLR

News

zacks.comIs Allarity Therapeutics, Inc. (ALLR) Outperforming Other Medical Stocks This Year?zacks.comJun 19

globenewswire.comAllarity Therapeutics to Present Trial-in-Progress Poster on Phase 2 Stenoparib Trial at ESMO Gynaecological Cancers Congress 2026globenewswire.comJun 18

zacks.comAre Medical Stocks Lagging Allarity Therapeutics, Inc. (ALLR) This Year?zacks.comJun 3

globenewswire.comAllarity Therapeutics Reports First Quarter 2026 Results and Continued Stenoparib Development in Multiple Cancersglobenewswire.comMay 15

Trade ALLR

About Allarity Therapeutics, Inc.

Allarity Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new cancer treatments. They utilize a unique "drug response predictor" technology to generate specific companion diagnostics, aiming to identify which patients will best respond to their various oncology therapeutics. The company's portfolio of investigational drugs for various cancers includes: Stenoparib: A poly-ADP-ribose polymerase (PARP) inhibitor currently in Phase 2 clinical trials for ovarian cancer. Dovitinib: A pan-tyrosine kinase inhibitor designed to treat renal cell carcinoma. IXEMPRA: A microtubule inhibitor used in the treatment of metastatic breast cancer. LiPlaCis: A liposomal formulation of cisplatin, undergoing Phase 2 clinical trials for metastatic breast cancer. 2X-111: A liposomal formulation of doxorubicin, also in Phase 2 studies for both metastatic breast cancer and glioblastoma multiforme. Established in 2004, Allarity Therapeutics maintains its headquarters in Cambridge, Massachusetts.

CEO: Thomas H. Jensen
IPO Date: Dec 21, 2021

Market Data

Open: $1.35
High: $1.48
Low: $1.28
Volume: 291.5K
Avg Volume: 192.6K
52W High: $2.35
52W Low: $0.769

Valuation

Market Cap: $23M
Enterprise Value: $24M
Dividend Yield: 0.00%

Financials

Free Cash Flow: $-15M
Revenue: $320k
Net Income: $-11M
Cash: $15M
Debt: $1.4M

Events

EarningsAug 21

EPS est. -0.25